What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below.
Documentation question rather than a pharmacological one, but about this compound specifically.
What should a certificate for this actually carry, given its structure? I suspect the answer differs from the generic advice, and I would rather ask than assume the generic advice transfers.
Thank you for the correction. I would rather find out here than later.
Taking post #5 at face value and following it one step further.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
That is a description of practice, not a recommendation of it.
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
Written from notes rather than memory, which is why the numbers are specific.
Read the full topic (14 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Stability of BPC-157 in solution: what has been measured — one year on
On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. A narrow question about Stability of BPC-157, deliberately narrow,…
|
+84 | 98 | 7.8k | 18h |
|
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. The question about Analytical…
|
+28 | 33 | 1.6k | 1mo |
|
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…
|
+77 | 84 | 54k | 11mo |
|
[2026 update] Publication patterns in the BPC-157 literature, examined
Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a question about a…
|
+15 | 19 | 11k | 4mo |
|
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about…
|
+50 | 55 | 7.8k | 2d |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…
|
+107 | 119 | 11k | 12mo |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. A follow-up question about retatrutide phase 2 obesity paper that I did not know to…
|
+19 | 23 | 16k | 2d |
|
What a well-designed human trial of a secretagogue would look like
What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about well-designed human trial in a…
|
2 | 7.2k | 18mo | |
|
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Secretagogues and glucose tolerance, and specifically the version of it that…
|
+64 | 70 | 52k | 17d |
|
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…
|
+7 | 12 | 7.7k | 2mo |